|
Daily Medical Update
Lupus nephritis
Saturday, September 19, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
Lupus (2026) - Network Meta-Analysis
Key Findings
- SOC+Tacrolimus, SOC+Voclosporin, SOC+Obinutuzumab, and SOC+Belimumab increased primary renal remission versus SOC alone, with benefit ratios of 1.91, 1.69, 1.41, and 1.32, respectively.
- Indirect comparisons favored SOC+Tacrolimus over SOC+Rituximab, +Anifrolumab, +Ocrelizumab, and +Abatacept, and favored SOC+Voclosporin over +Rituximab; no significant increase in serious or serious infectious event risk was detected among regimens.
📋 Practice Implication: For active lupus nephritis induction, CNI-containing triple therapy is a leading option when patient factors and local access support it; use the comparative ranking to guide regimen selection rather than treating all combinations as equivalent.
|
Annals of the rheumatic diseases (2025) - Practice Guideline
Key Findings
- The update finalized 4 overarching principles and 13 recommendations to improve care across kidney biopsy, treatment targets and milestones, immunomodulators, kidney protection, vaccination, cardiovascular and bone protection, family planning, and kidney failure management.
- The recommendations support strategies to reduce glucocorticoid exposure through tapering or withdrawal and address immune-therapy duration and refractory disease, with choices adjusted for severity, safety, cost, and local availability to improve long-term care.
📋 Practice Implication: Use the EULAR update as a structured framework for aligning biopsy decisions, response targets, maintenance planning, supportive care, and treatment de-escalation with disease severity and patient context.
|
International urology and nephrology (2026) - Meta-Analysis
Key Findings
- Voclosporin increased the likelihood of urine protein-to-creatinine ratio falling below 50% of baseline (HR 1.97, 95% CI 1.66-2.35) and below 0.5 g/g (HR 1.84, 95% CI 1.43-2.37) versus placebo.
- Complete and partial response rates were higher at 6 and 12 months, respectively, but overall adverse events and treatment-related serious adverse events significantly increased with voclosporin.
📋 Practice Implication: Voclosporin can strengthen early proteinuria and remission responses when added to standard therapy, but its use should be paired with deliberate adverse-event review and monitoring rather than assumed to be risk-neutral.
|
Rheumatology (Oxford, England) (2026) - Randomized Controlled Trial
Key Findings
- The core and extension studies were terminated early after a planned futility analysis; week-52 complete renal response was lower with secukinumab than placebo (24.2% vs 36.3%).
- No clinically meaningful improvement was observed in secondary endpoints, while treatment-emergent adverse events remained comparable between secukinumab and placebo.
📋 Practice Implication: Do not add secukinumab for active lupus nephritis outside a research setting; the negative renal-response result argues against routine IL-17-directed treatment for this indication.
|
Frontiers in immunology (2026) - Network Meta-Analysis
Key Findings
- Across 16 randomized trials involving 1994 patients, voclosporin-based triple therapy ranked highest for total remission (SUCRA 84.3%), followed by tacrolimus-based triple therapy (SUCRA 78.0%).
- No significant intergroup differences were observed in adverse events, serious adverse events, or discontinuations, but voclosporin had the highest infection-risk ranking (SUCRA 20.6%) and tacrolimus the second highest (27.0%).
📋 Practice Implication: When selecting a CNI regimen, balance the strong remission ranking of voclosporin or tacrolimus against infection susceptibility and establish proactive infection surveillance, especially for patients with substantial baseline risk.
|
|
💡
Summary
The 2025 EULAR update broadens kidney-involvement guidance across biopsy, treatment targets, immunomodulation, kidney protection, and management of refractory disease. Network meta-analyses favor calcineurin-inhibitor-containing triple regimens for remission, while voclosporin add-on therapy improves proteinuria and response rates but carries adverse-event and infection-monitoring concerns. Secukinumab failed to improve complete renal response in active lupus nephritis and was stopped early for futility.
|
|